Sequential Use of Efgartigimod and Romiplostim Restored Platelet Response in Two Multi-Refractory Thrombocytopenic Patients, Previously Treated with Thrombopoietin Receptor Agonists

Mediterr J Hematol Infect Dis. 2023 Mar 1;15(1):e2023021. doi: 10.4084/MJHID.2023.021. eCollection 2023.
No abstract available

Keywords: Chronic ITP; ITP; New agents; New drugs; Refractory ITP; Thrombopoietin.